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Abstract
Background: Vitamin D is important to health and dis-
ease. Liquid chromatography-tandem mass spec-
trometry (LC-MSMS) is considered the most accurate
technology for quantification of serum 25-hydroxy-
vitamin D (25OHD) which is the best biomarker for
estimating vitamin D nutritional status.
Methods: Serum was mixed with acetonitrile contain-
ing hexadeuterated 25-hydroxyvitamin D3 (d6-
25OHD3) and centrifuged 10 min at 15,634=g. The
supernatant was injected onto a turbulent flow pre-
paratory column then transferred to a polar endcap-
ped C18 analytical column. The mass spectrometer
was set for positive atmospheric pressure chemical
ionization.
Results: The analytical cycle time was 5.5 min. Inter-
and intra-assay CV for both analytes across three con-
centrations ranged from 3.8% to 14.2%. The method
was linear from 3.0 to 283.6 nmol/L for 25-hydroxy-
vitamin D3 (25OHD3) and 4.6 to 277.9 nmol/L for
25-hydroxyvitamin D2 (25OHD2), with an accuracy of
88.7%–118.7% and 90.7%–100.3%, respectively. No
carryover or ion suppression was observed. Compar-
ison with a radioimmunoassay using patient speci-
mens (ns527) showed a mean difference of 5.2%,
and diagnostic agreement of 80.9% with Deming
regression of slope 0.867, intercept 12.8, standard
error of estimate (SEE) 17.4, and rs0.8425.
Conclusions: The LC-MSMS method coupled with tur-
bulent flow technology for serum 25OHD quantitation
is rapid, efficient, and suitable for clinical testing.
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Introduction
Vitamin D has been recognized as the sunshine vita-
min and deficiency/insufficiency has been associated
with poor bone metabolism, weak muscle strength,
cancer risk and mortality, autoimmune disease, and
cardiovascular disease (1–3). Recently published
studies show links between vitamin D and various
diseases including muscle strength (4), cancer risk
and mortality (5–7), insulin resistance (8), and cardio-
vascular disease (9).
There are two common types of vitamin D: chole-
calciferol (D3) and ergocalciferol (D2). D3 is synthe-
sized in the skin from 7-dehydrocholesterol in cell
membranes upon exposure to UVB (290–320 nm).
D2 is derived primarily from yeast and produced exo-
genously by UV irradiation of ergosterol (2, 10). Both
dietary supplementation and sunshine exposure are
effective in preventing vitamin D deficiency (2, 10).
There is clear evidence that UV light exposure, con-
suming vitamin D-fortified food, and/or vitamin D
supplementation has a positive impact on serum
25-hydroxyvitamin D (25OHD) concentrations, and
adults can tolerate vitamin D at doses above the cur-
rent dietary reference intake levels (11–13). Though
both D2 and D3 have been used as supplements, D2
is less efficient compared with D3 for increasing
serum 25OHD (10, 14, 15). However, long-term treat-
ment with D2 and D3, 1000 IU daily, showed similar
effectiveness in increasing serum 25OHD (16).
Vitamin D in circulation is metabolized to 25OHD
in the liver and further metabolized to the active
metabolite, 1,25-dihydroxyvitamin D w1,25(OH)2Dx in
the kidney (10). The concentration of 1,25(OH)2D is
highly regulated by many factors including serum
parathyroid hormone and phosphorus (1, 2). The half-
lives of vitamin D, 25OHD, and 1,25(OH)2D are ;24 h,
3 weeks, and 4 h, respectively (17). Liver production
of 25OHD is not regulated significantly and is primar-
ily dependent on the availability of vitamin D (17).
Therefore, measuring total serum 25OHD is consid-
ered the best estimate of vitamin D nutritional status.
It is now generally accepted that serum 25OHD con-
centrations of 50 nmol/L (20 ng/mL) and 75 nmol/L
(30 ng/mL) are the cut-off thresholds for deficiency
and insufficiency, respectively (10, 18, 19). Vitamin D
insufficiency is recognized as an epidemic issue in
both children and adults (1, 10, 20).
Immunoassays and chromatography-based meth-
ods have been used to measure 25OHD in serum or
plasma. The International Vitamin D Quality Assess-
1566 Bunch et al.: Turbulent flow LC-MSMS 25-hydroxyvitamin D assay
Article in press - uncorrected proof
ment Scheme demonstrated that most commercial
25OHD methods were capable of producing reliable
results for samples containing only 25-hydroxyvita-
min D3 (25OHD3), but most methods had significant
bias compared to HPLC for samples with a substantial
proportion of 25-hydroxyvitamin D2 (25OHD2) (21).
Evaluation of current radioimmunoassay (RIA) and
chemiluminescent methods for serum 25OHD using
patient samples showed substantial variability among
the six methods, and the same methods used in dif-
ferent laboratories (22). Compared to a HPLC method
for 25OHD, significant positive proportional bias
was observed for immunoassays in the range of
20–50 nmol/L in serum samples before the patients
had D2 treatment. Also, all the immunoassays that
were evaluated under-estimated the 25OHD2 in sam-
ples following D2 treatment (23). A comprehensive
evaluation of seven methods using 291 EDTA plasma
samples (277 had no detectable 25OHD2 and 14
had 25OHD2 between 5 and 8 nmol/L) showed that
all methods, except HPLC, demonstrated considerable
negative bias compared to liquid chromatography-
tandem mass spectrometry (LC-MSMS) (24). For most
immunoassays, the deviation was more significant at
25OHD )75 nmol/L compared with those )75 nmol/L
(24).
Most HPLC methods require lengthy sample prep-
aration, including solid-phase extraction (25) and
liquid-liquid extraction (26), with a long HPLC chro-
matography time ranging from 10 to 30 min. Atten-
tion should be given to the late elution peaks which
might interfere with the analysis of succeeding sam-
ples (25). Although LC-MSMS is considered the most
accurate technology for 25OHD quantification (17, 27),
1a-hydroxyvitamin D3 (1aOHD3) (28) and the C3 epi-
mer of 25OHD (3-epi 25OHD) (29) could be significant
interferents due to the same molecular weight if not
separated by LC. Most LC-MSMS methods employ
deuterated 25OHD3 as internal standard. To improve
ionization efficiency, some methods employ a deriv-
atization strategy with a Cookson-type reagent (30) or
Diels-Alder derivatization (31). For direct measure-
ment, sample preparation could be cumbersome. In
general, sample preparation includes protein precipi-
tation followed by solid-phase extraction (32–34) or
liquid-liquid extraction (28, 35, 36). Turbulent flow
technology is a robust and rapid online purification
tool for high efficiency extraction (37, 38), and has
been used for online sample cleaning for serum
25OHD quantification (29). Here, we report a simple
and fast LC-MSMS method with online turbulent flow
extraction. We compared this method with a RIA
method using a large number of patient samples.
Materials and methods
Reagents and solutions
Methanol, acetone, acetonitrile, and isopropanol (Burdick
and Jackson High Purity Solvent) were from VWR (West
Chester, PA, USA). Type 1 water was from Millipore Synergy
System (Billerica, MA, USA). 25OHD2 and 25OHD3 were
G98% and 1aOHD3 was G97% pure by HPLC (Sigma-
Aldrich, St. Louis, MO, USA). Hexadeuterated-25-hydroxy-
vitamin D3 (d6-25OHD3) (99%-2H) and hexadeuterated-
25-hydroxyvitamin D2 (d6-25OHD2) (99%-2H) were procured
from Medical Isotopes (Pelham, NH, USA). A turbo prepar-
atory column, Cyclone-P 1.0=50 mm, and a polar endcapped
C18 column, Hypersil GOLD aQ 2.1=50 mm, 5 mm, were
purchased from Thermo Fisher (Waltham, MA, USA). The
solvent mixer (P/N G1312-87330) was from Agilent (Santa
Clara, CA, USA). The sampling vials (Waters, Milford, MA,
USA) were LC-MS certified and Axygen 96-well plates were
from VWR. ClinChek Serum 25OHD2 and 25OHD3 controls
were purchased from IRIS Technologies Inc (Olathe, KS,
USA). A stock solution for each 25OHD3 (nmol/Ls2.496=
ng/mL), d6-25OHD3 (nmol/Ls2.459=ng/mL), and 25OHD2
(nmol/Ls2.423=ng/mL) was made at a nominal concentra-
tion of 250 mmol/L. The final stock concentration was
calculated using a Beckman Coulter DU 800 UV/visible spec-
trophotometer (Fullerton, CA, USA) with molar extinction
coefficients of 17,950 (39) for 25OHD2 and 18,000 (40) for
25OHD3 at 265 nm. A set of calibration standards with com-
bined 25OHD3 and 25OHD2 at 200.0, 100.0, 50.0, 25.0, and
12.5 nmol/L for 25OHD3 and 194.0, 97.0, 48.5, 24.3,
12.1 nmol/L for 25OHD2 was prepared by serial dilution in
absolute ethanol and stored at –708C. Ethanolic calibrators
were used because human serum, bovine serum albumin,
and commercial steroid free serum all contained significant
amounts of 25OHD, based on our evaluation. To ensure the
matrix difference did not have an adverse impact on quan-
tification of patient samples, serum-based commercial con-
trols were included in each run. In addition, serum-based
samples with known added values were used in the preci-
sion and linearity studies to show the validity of ethanol-
based calibrators. A precipitation/internal standard solution
containing d6-25OHD3 at 103.3 nmol/L in acetonitrile was
stored at –208C.
Sample collection and preparation
Blood was collected in Vacutainer tubes with no additives
(BD, Franklin Lake, NJ, USA). The specimens were centri-
fuged immediately upon arrival at ;1500=g at room tem-
perature and assayed for 25OHD by RIA. Leftover samples
of serum were aliquoted, de-identified, and frozen at –708C
for the comparison study. Sample preparation consisted of
adding 250 mL internal standard to 100 mL of serum in either
polypropylene microcentrifuge tubes or 96 well plates. After
vortexing for 1 min, the mixture was centrifuged for 10 min
at 15,634=g for the microcentrifuge tubes and 3300=g for
the 96 well plates. In the microcentrifuge tubes, the super-
natant was transferred to sample vials and placed on the
autosampler. The plates were directly loaded into the auto-
sampler with 100 mL of the supernatant injected into the
system.
Turbulent flow LC-MSMS method
This method was developed on the Thermo TSQ Quantum
Access with a Cohesive front end using turbulent flow tech-
nology. Instrument software for this study consisted of Tune
Master 1.5, Aria 1.6.1, and Xcalibur 2.0.7. The duplex Cohe-
sive system consisted of a robotic sampling arm and a refrig-
erated sampling compartment for six 96-well plates followed
by two parallel and independent inline degassers, binary
HPLC pumps, and quaternary HPLC pumps. A solvent mixer
was placed between the sample injection port and the turbo
column to mix the different solvents in the samples (aceto-
nitrile) and the mobile phase (methanol), which could cause
significant peak broadening. Samples were loaded on the
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Figure 1 Chromatograms.
(A) A typical patient sample with mid levels of 25OHD2 and 25OHD3. Acceptable retention times (RT) for standards and
patients are 25OHD3 and d6-25OHD3 at 1.01"0.03 min and 25OHD2 at 1.04"0.03 min. (B) Chromatographic resolution
between 25OHD3 and 1aOHD3 with 25OHD3 eluting at 1.01 min and 1aOHD3 eluting at 1.17 min.
Cyclone-P turbo column which was washed afterwards. At
the transfer step, 100 mL of methanol from the transfer loop
eluted the analytes from the Cyclone-P turbo column to the
Hypersil GOLD aQ analytical column where separation
occurred with an isocratic elution of 95% methanol. The total
run time between two injections was 5.5 min if only one
channel was used. The mass spectrometer was set to posi-
tive ion mode with the atmospheric pressure chemical ioni-
zation probe. The discharge current was set to 2.0 A with the
capillary temperature at 2008C and the vaporizer temperature
at 2908C. The sheath gas was set to 55 U and aux gas to
25 U. Multiple reaction monitoring was set at the transitions
of 401.3™383.2 m/z for 25OHD3, 407.3™389.2 m/z for
d6-25OHD3, and 413.3™395.0 m/z 25OHD2. The collision
energy was 8 eV for 25OHD3 and 25OHD2 and 7 eV for
d6-25OHD3 and the tube lens for 25OHD3 was 110 V and for
d6-25OHD3 and 25OHD2 was 130 V. Data collection started
at 2.5 min into the HPLC run and continued for 1.25 min. A
representative patient chromatogram is displayed in Figure
1A. The turbulent flow and HPLC methodology is outlined
in Table 1.
RIA assay
The primary method for comparison was the DiaSorin RIA
(Stillwater, MN, USA) which was linear from 17.5 to
249.6 nmol/L. The intra-day variation (ns10) was 6.0% at
34.4 nmol/L and 5.5% at 120.6 nmol/L. Inter-day variation
(ns15) was 11.0% at 36.9 nmol/L and 10.5% at 136.8 nmol/L.
The lower limit of quantification (LLOQ) was 17.5 nmol/L.
Validation methods
Ion suppression was evaluated by post-column infusion of a
pure deuterated 25OHD2 and 25OHD3 solution while patient
samples were injected in the system. Two phospholipids
(lyso-phosphotidylcholine C16:0 and C18:0) were monitored
for potential coelution. Since 1aOHD3 has the same molec-
ular weight as 25OHD3 and was noted in a previous publi-
cation (28) as a possible interferent, we performed testing
by injecting an ethanolic solution containing both 1aOHD3
and 25OHD3.
The limit of detection was assessed by running saline
(ns20) and was determined to be 3 standard deviations (SD)
over the mean. A pool of patient samples with -12.5 nmol/L
of 25OHD2 and 25OHD3 was spiked with both 25OHD2 and
25OHD3. Then, linearity was examined in triplicate by seri-
ally diluting the spiked pool with saline to achieve the appro-
priate concentrations. The LLOQ was determined by the
lowest concentration levels in the linearity study with accu-
racy within 100%"20% and total CV within 20%. Both intra-
assay and inter-assay CVs were determined using three
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Table 1 LC conditions for turbo and analytical columns.
Process Time, s Turbo Flow rate, Analytical Flow rate,
column mL/min column mL/min
solvent solvent
A:B:C A:B
Turbulent flow extraction 55 60:40:0 4.0 60:40 0.80
on turbo column
Slow down pumps 5 60:40:0 0.2 60:40 0.55
Begin transfer from turbo 90 60:40:0 0.2 60:40 0.55
to analytical column
Clean turbo column, perform 45 0:0:100 2.0 5:95 0.85
separation on analytical column
Clean turbo column, perform 30 100:0:0 2.0 5:95 0.85
separation on analytical column
Load transfer loop and clean 60 0:100:0 4.0 0:100 0.85
analytical columns
Equilibrate turbo and analytical 45 60:40:0 4.0 60:40 0.80
columns
Mobile phase A, water; mobile phase B, methanol; mobile phase C, organic cocktail containing 70% acetonitrile, 20% isopro-
panol, and10% acetone.
concentrations of patient samples in the sequencemid-high-
low-mid-mid-low-low-high-high-mid run twice a day for 5
days using CLSI EP10-A3 guidelines (Wayne, PA, USA). Car-
ryover was determined by analysis of three extractions of
the sequence (low1-high-low2) where low2 was a re-injection
of the low1. A passing test meant low1 and low2 differed by
-20% and the low2 was within 3 SDs of the low1 value. The
SD was determined using low1 values. High values above
the linearity of the assay were diluted to within the linear
range and the value was back calculated. Comparisons using
Deming regression, Passing-Bablok regression, and analysis
for diagnostic agreement were performed between the new
LC-MSMS assay and the RIA method. Statistics were calcu-
lated using Excel (Microsoft, Redmond, WA, USA), EP Eva-
luator Release 8 (David G. Rhoads Associates, Kennett
Square, PA, USA), and Analyze-it (Analyse-it Software, Ltd,
Leeds, UK).
Ethical approval
Utilizing leftover de-identified clinical samples did not
require institutional Review Board review.
Results and discussion
Chromatography
During the chromatography optimization, we found
that there was a narrow range of mobile phase com-
positions for efficiently retaining the 25OHD analytes
on the turbo column for purification. We found that
60% water with 40% methanol retained the analytes
on the turbo column best, without causing peak
broadening. Acid is often added to mobile phases
for LC-MSMS because it improves ionization (41).
Thus, formic acid was tested for ionization improve-
ment by infusing the analytes and d6-25OHD3 in the
presence of mobile phase with and without 0.1% for-
mic acid. There was no significant difference between
the two conditions. The chromatographic run time
was 5.5 min/injection in a single channel. When two
LC channels were used at the same time, the average
run time in a batch was reduced to 3.0 min/injection.
The retention time (mean"SD) for 25OHD3 and d6-
25OHD3 was 1.01"0.1 min (ns571) and for 25OHD2
was 1.04"0.1 min (ns432) in serum samples (Figure
1). There was a significant peak in the 25OHD2 chan-
nel at 0.9 min (Figure 1A). A full spectra scan was
performed (data not shown) and it was found to have
a significantly different fragmentation spectrum com-
pared with 25OHD2.
Interferences
Interferences are less common with LC-MSMS meth-
ods due to the inherent specificity of MSMS. How-
ever, a compound with the same molecular weight
and ionization characteristics can possibly interfere.
Interference studies were conducted by obtaining
pure compound and spiking these into ethanolic stan-
dards with known 25OHD concentrations. This was
injected into the system to see if it showed up on the
chromatogram with a close retention time to the
analytes. Due to previously published data, 1aOHD3
was considered a possible interferent for 25OHD3
and therefore was tested. The retention time of this
compound was 1.17 min compared to 1.01 min for
25OHD3 with baseline separation (Figure 1B). In addi-
tion, a 250 nmol/L solution of 1aOHD3 had a peak
height similar to a 12.5 nmol/L peak of 25OHD3 mean-
ing a much lower ionization efficiency of 1aOHD3
under the current conditions compared with 25OHD3.
The 3-epi 25OHD is a known interferent for patients
under the age of 1 year (29). At the time of method
validation, a commercial 3-epi 25OHD was not avail-
able for interference testing. Therefore, caution
should be used for interpreting results in this age
group. Other possible interferents are phospholipids
found naturally in human blood. These compounds
have similar characteristics as 25OHD2 and 25OHD3.
Lyso-phosphotidylcholine C16:0 and C18:0 were mon-
itored during development and showed no interfer-
ence with either 25OHD3 or 25OHD2 (data not
shown). Also, due to their relatively high molecular
weight (500–1000) compared to 25OHD, they were not
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Table 2 Linearity and recovery.
Analyte Add-in, Expected, Mean, Analytical %CV
nmol/L nmol/L nmol/L recovery, %
25OHD2 2.36 2.39 2.98 125.0 29.2
4.73 4.78 4.60 96.2 4.3
7.10 7.18 7.20 100.3 7.5
9.46 9.57 9.45 98.8 6.9
18.93 19.13 18.78 98.1 5.3
37.86 38.26 36.66 95.8 5.0
75.72 76.53 72.57 94.8 4.8
151.44 153.06 147.15 96.1 3.0
302.88 306.12 277.92 90.7 1.8
25OHD3 2.44 2.49 2.95 118.7 14.5
4.87 4.98 5.42 109.0 10.2
7.31 7.47 7.81 104.7 3.1
9.75 9.96 10.43 104.9 2.3
19.50 19.92 18.89 94.7 3.9
39.00 39.84 37.94 95.1 1.4
78.00 79.68 72.63 91.0 1.1
156.00 159.37 144.82 90.7 2.3
312.00 318.74 283.55 88.7 2.3
Table 3 Precision data according to CLSI EP10-A3 protocol.
25OHD3 25OHD2
Low Mid High Low Mid High
Mean, nmol/L 33.4 61.0 120.5 18.5 70.6 139.9
Total SD 3.0 4.6 11.4 3.1 7.8 15.6
Intra-assay SD 1.6 2.3 7.4 1.7 3.2 9.0
Inter-assay %CV 7.7 6.6 7.1 14.2 10.0 9.2
Intra-assay %CV 4.9 3.8 6.1 9.3 4.6 6.4
Table 4 Method comparison results by Deming regression.
Comparison Analyte n Slope (95% CI) Intercept, nmol/L Standard error of r % difference
method (95% CI) estimate, nmol/L of mean
RIA 25OHD 527 0.867 (0.825–0.909) 12.8 (9.5–16.1) 17.4 0.8425 5.2
RIA 25OHD3a 216 0.865 (0.802–0.927) 9.0 (4.9–13.2) 14.0 0.8595 1.7
a25OHD2 is below LLOQ.
viewed as a major interferent (42). Ion suppression
was examined by monitoring total ion current with
20 patient samples individually injected through a T-
connection with a post-column line prior to the mass
spectrometer with a d6-25OHD3 and d6-25OHD2 eth-
anol solution infused at 5 mL/min. No ion suppression
was observed.
Assay validation
Assay calibration for 25OHD3 and 25OHD2 was per-
formed with 25OHD2 and 25OHD3 at five concentra-
tions prepared by serial dilution in absolute ethanol
and stored at –708C until use. Quantitation was
achieved based on the peak area ratios of analytes to
the internal standard. The d6-25OHD3 was used as the
internal standard for both 25OHD3 and 25OHD2 due
to the fact that d6-25OHD2, while recently available,
has a molecular weight of 418.2. With the loss of a
water molecule from d6-25OHD2 parent ion, a frag-
ment with 401.2 m/z was formed interfering with
25OHD3 quantification. The limit of detection was
1.7 nmol/L and 1.2 nmol/L for 25OHD3 and 25OHD2,
respectively, determined using 20 replicates of saline.
From serial dilutions, linearity was determined to be
3.0–283.6 nmol/L for 25OHD3 and 4.6–277.9 nmol/L
for 25OHD2, with an accuracy of 88.7%–118.7% and
90.7%–100.3%, respectively. The LLOQ was 3.0 nmol/L
for 25OHD3 and 4.6 nmol/L for 25OHD2, respectively
based on the precision and accuracy data in the linea-
rity study (Table 2). The intra-assay and inter-assay
CVs (3.8–14.2, Table 3) were determined using patient
samples at three concentrations based on CLSI EP10-
A3 guidelines (43). No significant carryover was
observed by testing the spiked patient samples with
low1 (mean: 10.2 nmol/L)–high (713.3 nmol/L)–low2
(10.2 nmol/L) for 25OHD2 and low1 (38.9 nmol/L)–high
(577.1 nmol/L)–low2 (41.2 nmol/L) for 25OHD3.
Method comparison
We compared the newly developed method with the
DiaSorin RIA using left-over patient samples. The dis-
tribution of vitamin D concentrations was near a nor-
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Figure 2 Bland-Altman plot. The mean of percent differences was –7.6% with a standard deviation of 26.2%.
mal distribution based upon visual inspection of the
histogram of patient data (data not shown). Table 4
contains the comparison data using Deming regres-
sion between our LC-MSMS and the DiaSorin RIA
method (ns527). The regressions had a slope 0.87,
r)0.84, and mean difference within 5.2% using all
samples (ns527) or samples (ns216) with 25OHD2
concentrations below the LLOQ, indicating equivalent
recoveries of both 25OHD2 and 25OHD3 for the RIA
method. To compare our results with a previously
published comparison conducted between a LC-
MSMS method and several immunoassays, non-
parametric Passing-Bablok regression (ns527) was
performed. The regression showed a slope of 0.96
(95% CI: 0.90–1.02) and an intercept of 6.64 nmol/L
(3.74–10.14) which compared favorably to the slope
of 0.64 (reverse relationship) between IDS-RIA (IDS
Ltd., Tyne and Wear, UK) and LC-MSMS (24). A Bland-
Altman plot did not reveal concentration-depended
bias between LC-MSMS and the RIA (Figure 2), as
opposed to a previous observation between IDS-RIA
and LC-MSMS (24). We calculated diagnostic agree-
ment between LC-MSMS and RIA using G75 nmol/L
as sufficient vitamin D status and found this to be
80.9%. For 0–50, 51–74 and G75.0 nmol/L cut-offs,
agreement was 68.5% based on the deficient, insuf-
ficient, and sufficient levels commonly described in
the literature (10). Under the 2nd diagnostic agree-
ment breakdowns, LC-MSMS overestimated values
22.9% of the time and underestimated 8.6%, com-
pared to RIA. Multivariate regression was performed
using all patient data (ns527) to determine the con-
tribution of 25OHD3 and 25OHD2 by our LC-MSMS
to the total by RIA. The multivariate equation with
95% CI in parentheses was RIAs0.93(0.89–0.97)=
25OHD3q1.04(0.98–1.10)=25OHD2, R2s0.90. This
equation along with the correlation data demonstrat-
ed that the RIA method and LC-MSMS were compar-
able in determining 25OHD concentrations in patient
samples. Also, the difference between the two meth-
ods was much smaller than the difference observed
between another LC-MSMS and the IDS RIA in a pre-
vious report (24). Therefore, our LC-MSMS method
may be used in the clinical evaluation of serum
25OHD without significant overall deviation (mean
differences5.2%) from the RIA method, which has
been used in many clinical trials. It is important to
have comparable results obtained using different
methodologies in clinical laboratories to avoid com-
plication of clinical interpretation (44).
In conclusion, we developed and validated a novel
LC-MSMS method with a turbulent flow online extrac-
tion technology to quantitate serum 25OHD2 and
25OHD3. The method is rapid and requires little
manual sample preparation. Our comparison study
showed that the LC-MSMS provided comparable
results with the DiaSorin RIA with a mean difference
of only 5.2%.
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